| Literature DB >> 29503800 |
María Araque1, Indira Labrador1.
Abstract
OBJECTIVES: Antimicrobial resistant extended-spectrum-β-lactamase-producing Enterobacteriaceae (ESBL-PE) have been shown to be present in healthy communities. This study examined healthy children from the rural Andean village of Llano del Hato, Mérida, Venezuela, who have had little or no antibiotic exposure to determine the prevalence of fecal carriage of ESBL-producing Escherichia coli (ESBL-EC).Entities:
Keywords: CTX-M-15; Enterobacteriaceae; Extended-spectrum-β-lactamases; Venezuela; fecal carriage; healthy children
Year: 2018 PMID: 29503800 PMCID: PMC5831685 DOI: 10.24171/j.phrp.2018.9.1.03
Source DB: PubMed Journal: Osong Public Health Res Perspect ISSN: 2210-9099
Demographic and epidemiological characteristics associated with ESBL-producing E. coli from healthy children from a rural Andean village in Venezuela.
| Characteristics | Detection of ESBL | Multivariate | ||
|---|---|---|---|---|
| Positive | Negative | |||
|
| ||||
| Male | 14 (51.9) | 28 (54.9) | 1 | |
|
| ||||
| Female | 13 (48.1) | 23 (45.1) | 1.130 (0.444–2.880) | 0.9853 |
|
| ||||
|
| ||||
| 1 – ≤ 2.5 | 7 (25.9) | 37 (72.6) | 1 | |
|
| ||||
| ≥ 2.5 – ≤5 | 20 (74.1) | 14 (27.4) | 7.551 (2.621–21.754) | 0.0002 |
|
| ||||
|
| ||||
| Still breast-feeding | 6 (22.2) | 31 (60.8) | ||
|
| ||||
| Two or more different type of animal-origin food | 21 (77.8) | 20 (39.2) | 5.425 (1.865–15.778) | 0.0026 |
|
| ||||
|
| ||||
| Water | 5 (18.5) | 22 (43.1) | 1 | |
|
| ||||
| Water and soap | 22 (81.5) | 29 (56.9) | 3.338 (1.091–10.213) | 0.0543 |
|
| ||||
|
| ||||
| No | 9 (33.3) | 23 (45.1) | ||
|
| ||||
| Yes | 18 (66.7) | 28 (54.9) | 0.609 (0.230–1.609) | 0.4455 |
|
| ||||
|
| ||||
| No | 22 (81.5) | 46 (90.2) | 1 | |
|
| ||||
| Yes | 5 (18.5) | 5 (9.8) | 2.091 (0.548–7.985) | 0.4597 |
|
| ||||
|
| ||||
| No | 22 (81.5) | 50 (98.0) | 1 | |
|
| ||||
| Yes | 5 (18.5) | 1 (2.0) | 11.364 (1.252–103.11) | 0.0304 |
Figure 1Forest plot showing the association of the fecal carriage of ESBL-EC with epidemiological variables.
The values of Cramer’s V confirmed a relatively strong effect size (0.447) of the variable ≥ 2.5 years – ≤5 years, and a moderate effect (0.367) of the variable “food ingestion of animal origin.”
Antimicrobial susceptibility of E. coli strains isolated from healthy children from a rural Andean village in Venezuela.
| Antibiotic | MIC Range (μg/ml) | Antimicrobial susceptibility | ||
|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | ||
| Ampicillin/sulbactam | ≤8/4 – ≥32/16 | 77 (98.7) | - | 1 (1.3) |
| Piperacillin/tazobactam | ≤16/4 – ≥128/4 | 78 (100) | - | 0 (0.0) |
| Cefoxitin | ≤8 – ≥32 | 73 (93.6) | - | 5 (6.4) |
| Ceftazidime | ≤4 – ≥16 | 52 (66.7) | - | 26 (33.3) |
| Cefotaxime | ≤1 – ≥4 | 51 (65.4) | - | 27 (34.6) |
| Cefepime | ≤2 – ≥16 | 60 (72.9) | - | 18 (23.1) |
| Aztreonam | ≤4 – ≥16 | 52 (66.7) | - | 26 (33.3) |
| Ertapenem | ≤0,5 – ≥32 | 78 (100) | - | 0 (0.0) |
| Imipenem | ≤1 – ≥4 | 78 (100) | - | 0 (0.0) |
| Meropenem | ≤1 – ≥4 | 78 (100) | - | 0 (0.0) |
| Amikacin | ≤16 – ≥64 | 71 (91.0) | 2 (2.6) | 5 (6.4) |
| Gentamicin | ≤4 – ≥16 | 72 (92.3) | - | 6 (7.7) |
| Nalidixic acid | ≤16 – ≥32 | 72 (92.3) | 2 (2.6) | 4 (5.1) |
| Ciprofloxacin | ≤0,06– ≥1 | 71 (91.0) | 3 (3.8) | 4 (5.1) |
| Tigecycline | ≤0,1 – ≥16 | 78 (100) | - | 0 (0.0) |
| Colistin | ≤0,5 – ≥64 | 78 (100) | - | 0 (0.0) |
MIC: minimal inhibitory concentration.
Susceptibility profile of E. coli strains isolated from healthy children from a rural Andean village in Venezuela.
| Susceptibility profile of Escherichia coli | |||
|---|---|---|---|
| ESBL | non-ESBL | ||
| ESBL + | 17 (63.0) | Susceptible | 44 (86.3) |
| ESBL + GEMR | 2 (7.4) | AMKI | 2 (3.9) |
| ESBL + NALR | 2 (7.4) | CIPI | 2 (3.9) |
| ESBL + AMKR | 1 (3.7) | NALI | 1(2.0) |
| ESBL + NALR + CIPR | 1 (3.7) | NALR | 1(2.0) |
| ESBL + AMKR + GEMR | 1 (3.7) | NALI + CIPI | 1(2.0) |
| ESBL + AMKR + GEMR + CIPR | 3 (11.1) | ||
| Total | 27 (100) | Total | 51 (100) |
AMK: amikacin; CIP: ciprofloxacin; R: resistant; I: intermediate susceptibility; ESBL: extended-spectrum-β-lactamase; GEM: gentamicin; NAL: nalidixic acid;
Distribution of blaESBLs genes according to the phylogenetic group of E. coli strains.
| Gene | Phylogenetic group | Total | |||
|---|---|---|---|---|---|
| A | B1 | B2 | D | ||
| 9 | 2 | 6 | 2 | 19 (70.4) | |
| 1 | 1 | 1 | 0 | 3 (11.1) | |
| 2 | 0 | 0 | 0 | 2 (7.4) | |
| 1 | 0 | 1 | 0 | 2 (7.4) | |
| 1 | 0 | 0 | 0 | 1 (3.7) | |
| Total (%) | 14 (51.9) | 3 (11.1) | 8(29.6) | 2 (7.4) | 27 (100) |
Figure 2Hierarchical clustering dendogram demonstrating phylogenetic and resistance profiling of ESBL-EC.
Analysis based on clinical, epidemiological and molecular characteristics identified 2 distinct clusters of child fecal carriage of ESBL-EC. Note the presence of 2 subgroups (major cluster) with similar relationships of 100%. Children with a lower degree of similarity (≤65%) were observed in the minor cluster.
AMK: amikacin; CIP: ciprofloxacin; GEM: gentamicin; N°: children (ESBL-EC positive); NAL: nalidixic acid; PG: phylogenetic group; Rest. Profile: resistance profile.